AKT1 and leukemia: In leukemia, selective mTORC1 inhibitor RAD001 and novel allosteric AKT inhibitor MK-2206 synergistically reduced the cell viability, induced cell cycle arrest in G0/G1 phase, and led to apoptosis and autophagy in precursor acute lymphoblastic leukemia cell lines and primary cells (47).